Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07209410 · ClinicalTrials.gov registry record · Phase 4
Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma
A Phase 4 study of Glaucoma, sponsored by Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT07209410 is a Phase 4 study of Glaucoma that is actively recruiting participants, run by Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,. The registered enrollment target is 35 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07209410, a Phase 4 study of Glaucoma, is actively recruiting participants, sponsored by Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the effect of brimonidine tartrate 0.025% on conjunctival hyperemia in patients treated with netarsudil 0.02%/latanoprost 0.005% mono-therapy for intraocular pressure lowering.
Conditions Studied
Interventions
- DRUG Brimonidine Tartrate Ophthalmic 0.025%
Study Locations (1)
Missouri
- Vision Source - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-11-01 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07209410
The ClinicalTrials.gov registry entry for NCT07209410 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (96% lower). The listed sponsor is Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 1 intervention - of which Brimonidine Tartrate Ophthalmic 0.025% is the first listed.
NCT07209410 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT07209410 about?
NCT07209410 is a clinical study titled "Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma". To evaluate the effect of brimonidine tartrate 0.025% on conjunctival hyperemia in patients treated with netarsudil 0.02%/latanoprost 0.005% mono-therapy for intraocular pressure lowering.
What is the current status of trial NCT07209410?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2025-11-01. Estimated completion is 2027-06-01.
What conditions does trial NCT07209410 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT07209410?
The interventions under investigation include: Brimonidine Tartrate Ophthalmic 0.025% (DRUG).
Who is sponsoring clinical trial NCT07209410?
This trial is sponsored by Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07209410 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Retinal Blood Flow and Autoregulation
RECRUITING · Phase 4
-
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
RECRUITING · Phase 4
-
Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy
COMPLETED · Phase 4
-
Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost
COMPLETED · Phase 4
-
Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance
COMPLETED · Phase 4
-
Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.